Cover Image
市場調查報告書

OPKO Health, Inc.- 產品平台檢討

OPKO Health, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 200985
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
OPKO Health, Inc.- 產品平台檢討 OPKO Health, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月27日 內容資訊: 英文 81 Pages
簡介

OPKO Health, Inc.(原eXegenics, Inc.)是開發並產品化各種新型診斷技術和藥品的生物製藥公司。同時也生產帕金森氏症和氣喘等治療藥。

本報告提供OPKO Health, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

OPKO Health, Inc.的基本資料

OPKO Health, Inc.概要

  • 主要資訊
  • 企業資料

OPKO Health, Inc.:R&D概要

  • 主要的治療範圍

OPKO Health, Inc.:開發平台(管線)的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

OPKO Health, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

OPKO Health, Inc.:藥物簡介

  • calcifediol MR
  • fermagate
  • MOD-4023
  • CTAP-201
  • lunacalcipol
  • SCH-900978
  • MOD-5017
  • MOD-9017
  • OPK-0018
  • CTA-091
  • Drug For Atherosclerosis
  • Drug For Rheumatoid Arthritis
  • Flu Vaccine
  • MOD-1001
  • MOD-1002
  • MOD-5014
  • MOD-6030
  • MOD-7023
  • MOD-9013
  • Oligonucleotide For Dravet Syndrome
  • Oligonucleotide For MPS-1
  • Oligonucleotide For Rett Syndrome
  • Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia
  • SR-3306
  • Drugs to Inhibit CYP24 for CKD and Pre-CKD

OPKO Health, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

OPKO Health, Inc.:最近的開發平台趨勢

OPKO Health, Inc.:暫停中的計劃

OPKO Health, Inc.:企業發表

OPKO Health, Inc.:總公司和子公司的所地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08038CDB

Summary

Global Markets Direct's, 'OPKO Health, Inc. - Product Pipeline Review - 2016', provides an overview of the OPKO Health, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by OPKO Health, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of OPKO Health, Inc.
  • The report provides overview of OPKO Health, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses OPKO Health, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features OPKO Health, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate OPKO Health, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for OPKO Health, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding OPKO Health, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • OPKO Health, Inc. Snapshot
    • OPKO Health, Inc. Overview
    • Key Information
    • Key Facts
  • OPKO Health, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • OPKO Health, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • OPKO Health, Inc. - Pipeline Products Glance
    • OPKO Health, Inc. - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • OPKO Health, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • OPKO Health, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • OPKO Health, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • OPKO Health, Inc. - Drug Profiles
    • calcifediol MR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fermagate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-4023
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTAP-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lunacalcipol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-5014
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-6031
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CTA-091
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CUR-1916
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-1001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-1002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-6030
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-7023
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-9013
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-9017
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Mucopolysaccharidosis I
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide For Rett Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Hearing Loss
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SR-3306
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Atherosclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Lipoprotein Signal Peptidase for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OPK-0018
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • OPKO Health, Inc. - Pipeline Analysis
    • OPKO Health, Inc. - Pipeline Products by Target
    • OPKO Health, Inc. - Pipeline Products by Route of Administration
    • OPKO Health, Inc. - Pipeline Products by Molecule Type
    • OPKO Health, Inc. - Pipeline Products by Mechanism of Action
  • OPKO Health, Inc. - Recent Pipeline Updates
  • OPKO Health, Inc. - Dormant Projects
  • OPKO Health, Inc. - Company Statement
  • OPKO Health, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • OPKO Health, Inc., Key Information
  • OPKO Health, Inc., Key Facts
  • OPKO Health, Inc. - Pipeline by Indication, 2016
  • OPKO Health, Inc. - Pipeline by Stage of Development, 2016
  • OPKO Health, Inc. - Monotherapy Products in Pipeline, 2016
  • OPKO Health, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • OPKO Health, Inc. - Out-Licensed Products in Pipeline, 2016
  • OPKO Health, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • OPKO Health, Inc. - Filing rejected/Withdrawn, 2016
  • OPKO Health, Inc. - Phase III, 2016
  • OPKO Health, Inc. - Phase II, 2016
  • OPKO Health, Inc. - Phase I, 2016
  • OPKO Health, Inc. - Preclinical, 2016
  • OPKO Health, Inc. - Discovery, 2016
  • OPKO Health, Inc. - Unknown, 2016
  • OPKO Health, Inc. - Pipeline by Target, 2016
  • OPKO Health, Inc. - Pipeline by Route of Administration, 2016
  • OPKO Health, Inc. - Pipeline by Molecule Type, 2016
  • OPKO Health, Inc. - Pipeline Products by Mechanism of Action, 2016
  • OPKO Health, Inc. - Recent Pipeline Updates, 2016
  • OPKO Health, Inc. - Dormant Developmental Projects,2016
  • OPKO Health, Inc., Subsidiaries

List of Figures

  • OPKO Health, Inc. - Pipeline by Top 10 Indication, 2016
  • OPKO Health, Inc. - Pipeline by Stage of Development, 2016
  • OPKO Health, Inc. - Monotherapy Products in Pipeline, 2016
  • OPKO Health, Inc. - Out-Licensed Products in Pipeline, 2016
  • OPKO Health, Inc. - Pipeline by Top 10 Target, 2016
  • OPKO Health, Inc. - Pipeline by Route of Administration, 2016
  • OPKO Health, Inc. - Pipeline by Molecule Type, 2016
  • OPKO Health, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top